Identifying conditions that maximize the structural stability of a biologic’s native state is essential for developing therapeutics, formulations, and process development conditions. In this GEN ...

Bioprocessors must minimize the aggregation of therapeutic proteins, but that’s not an easy task. Proteins can aggregate during any step from manufacturing to administering a drug. “The aggregation ...

Researchers have identified a backup mechanism of protein quality control which prevents the toxic effects of protein aggregation in specific tissues when normal methods of molecular monitoring fail.

The accumulation of misfolded proteins in the brain is central to the progression of neurodegenerative diseases like Huntington's, Alzheimer's and Parkinson's. But to the human eye, proteins that are ...

The COVID-19 pandemic brought about by the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) led to the disruption of the global economy and the loss of human lives. Studies are still ...

Scientists at Northwestern and Case Western Reserve universities have developed the first polymer-based therapeutic for Huntington's disease, an incurable, debilitating illness that causes nerve cells ...

Researchers from the Babraham Institute, UK, and the German Center for Neurodegenerative Diseases (DZNE) have identified a backup mechanism of protein quality control which prevents the toxic effects ...